Figure 3
Patient’s disease course (12 months-follow-up). CT: computed tomography; MRI: magnetic resonance imaging; PET: positron emission tomography; TCZ: tocilizumab 8 mg/kg; R-CVP: rituximab 375 mg/m3, cyclophosphamide 750 mg/m3, vincristine 1.4 mg/m3 and prednisone 40 mg/m3; RTX: rituximab 375 mg/m3; Hb: hemoglobin; PLT: platelet counts; CRP: C reactive protein; IL6: interleukin 6.